Dry-eye treatment shows promising Phase II results Full Text
Ophthalmology Times Europe , 05/23/2011
SARcode's lead investigational molecule, SAR 1118, demonstrated promising results in a Phase II study of dry eye disease, according to data presented at this year's Association for Research in Vision and Ophthalmology (ARVO) meeting.



